Literature DB >> 9478943

Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery.

B Fang1, L Ji, M Bouvet, J A Roth.   

Abstract

A synthetic GAL4-responsive promoter consisting of five GAL4-binding sites and a TATA box (GAL4/TATA) was evaluated for its transcriptional activity in an adenoviral backbone using luciferase as the reporter. Basal luciferase activities in vitro were the same for cells infected with either adenovirus-containing luciferase cDNA driven by GAL4/TATA (Ad/GT-Luc) or adenovirus-containing luciferase cDNA not driven by a promoter (Ad/PO-Luc). In vitro induction of GAL4/TATA by coinfection of cells with adenovirus expressing the GAL4/VP16 fusion protein (Ad/3-phosphoglycerate kinase (PGK)-GV16) was dose-dependent and reached as high as 4 x 10(4)- to 9 x 10(4)-fold above basal levels when GAL4/TATA and GAL4/VP16 were delivered at a ratio of 10:1. In vivo studies in Balb/c mice showed no detectable luciferase activities in liver or other tissues examined in mice infused with either Ad/GT-Luc or Ad/PO-Luc. High levels of luciferase activity were, however, elicited when animals were infused with Ad/GT-Luc and Ad/PGK-GV16. Together, these results suggest that combination of the GAL4 gene regulatory system with adenovirally mediated in vivo gene delivery may be applicable to the in vivo evaluation of promoter activities and in vivo targeting of gene expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9478943     DOI: 10.1074/jbc.273.9.4972

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.

Authors:  W Zhou; S Dai; H Zhu; Z Song; Y Cai; J B Lee; Z Li; X Hu; B Fang; C He; X Huang
Journal:  Gene Ther       Date:  2017-01-11       Impact factor: 5.250

2.  Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.

Authors:  Xiang Yan; Li Wang; Ran Zhang; Xingxiang Pu; Shuhong Wu; Lili Yu; Ismail M Meraz; Xiaoshan Zhang; Jacqueline F Wang; Don L Gibbons; Reza J Mehran; Stephen G Swisher; Jack A Roth; Bingliang Fang
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

3.  Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters.

Authors:  M Iyer; L Wu; M Carey; Y Wang; A Smallwood; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy.

Authors:  M Iyer; F B Salazar; X Lewis; L Zhang; L Wu; M Carey; S S Gambhir
Journal:  Transgenic Res       Date:  2005-02       Impact factor: 2.788

5.  Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells.

Authors:  Dietmar Jacob; Guido Schumacher; Marcus Bahra; John Davis; Hong-Bo Zhu; Li-Dong Zhang; Fuminori Teraishi; Peter Neuhaus; Bing-Liang Fang
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

6.  Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma.

Authors:  Joe Y Chang; Xiaochun Zhang; Ritsuko Komaki; Rex Cheung; Bingliang Fang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-04-01       Impact factor: 7.038

7.  Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.

Authors:  Wenxian Hu; John J Davis; Hongbo Zhu; Fengqin Dong; Wei Guo; Jian Ang; Henry Peng; Z Sheng Guo; David L Bartlett; Stephen G Swisher; Bingliang Fang
Journal:  Cancer Biol Ther       Date:  2007-08-12       Impact factor: 4.742

8.  Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.

Authors:  Xiaochun Zhang; Ritsuko Komaki; Li Wang; Bingliang Fang; Joe Y Chang
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.

Authors:  Yuanqing Wu; Bingliang Fang; Xiulan Q Yang; Li Wang; Dongning Chen; Victor Krasnykh; Bing Z Carter; Jeffrey S Morris; Imad Shureiqi
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

10.  JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase.

Authors:  W Hu; W Hofstetter; W Guo; H Li; A Pataer; H H Peng; Z S Guo; D L Bartlett; A Lin; S G Swisher; B Fang
Journal:  Cancer Gene Ther       Date:  2008-06-06       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.